ArriVent BioPharma Inc
Research ArriVent BioPharma Inc (AVBP) on Bullrun: market cap USD 1.51B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAVBP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.51B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 145.24M
- Free cash flow-USD 41.89M
Valuation Snapshot
latest market cap is USD 1.51B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 166.31M | -USD 160.59M | n/a | -4.32 | USD 45.54M | USD 14.00K | USD 307.22M |
| FY2024 | USD 0 | -USD 80.49M | -USD 70.21M | n/a | -2.56 | USD 74.29M | USD 176.00K | USD 257.65M |
| FY2023 | n/a | -USD 69.33M | n/a | n/a | -32.38 | USD 150.39M | USD 317.00K | -USD 153.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.51B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 830.58M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 897.95M | n/a | n/a | n/a |
About ArriVent BioPharma Inc
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
Related stock research
Other Healthcare stocks
Adicet Bio Inc (1IJ)
Cartesian Therapeutics, Inc. (1S70)
QUOIN PHARMACEUT.ADR5000 (2EB0)
Aardvark Therapeutics Inc (AARD)
Abeona Therapeutics Inc (ABEO)
Acumen Pharmaceuticals Inc (ABOS)
Absci Corp (ABSI)
Arbutus Biopharma Corp (ABUS)
ABVC BioPharma Inc (ABVC)
Acadia Pharmaceuticals Inc (ACAD)
Adicet Bio Inc (ACET)
Achieve Life Sciences Inc (ACHV)
Frequently asked questions
What is ArriVent BioPharma Inc's market cap?
ArriVent BioPharma Inc's market capitalization is USD 1.51B.
What does ArriVent BioPharma Inc do?
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.